1956. Persistence of Immune Response and Safety of an Adjuvanted Recombinant Zoster Vaccine in Older Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine: End-of-Study Results of a Phase III, Group-Matched, Clinical Trial
Session: Poster Abstract Session: Clinical Trials
Saturday, October 6, 2018
Room: S Poster Hall
Posters
  • GSK-IDWEEK 2018 - poster 1956.pdf (652.2 kB)
  • Background: Herpes zoster (HZ), caused by reactivation of varicella-zoster virus (VZV), typically manifests as a dermatomal rash and can result in complications, such as postherpetic neuralgia. HZ risk increases with age due to age-related decline of immunity. At time of study start, Zoster Vaccine Live (ZVL), containing live-attenuated VZV was recommended for vaccination in adults ≥60 years of age. Efficacy of ZVL declines with time since vaccination and increasing age. We evaluated immunogenicity and safety of Adjuvanted Recombinant Zoster Vaccine (RZV) containing truncated form of VZV glycoprotein E (gE) in adults vaccinated with ZVL ≥5 years before (HZ-PreVac) and ZVL-naïve adults (HZ-NonVac). In October 2017, the Advisory Committee on Immunization Practices recommended revaccination of ZVL recipients with RZV, based on available data, including 1 month (M) post-dose 2 results of this study (M3). Here we present immunogenicity and safety results up to 12 months post-dose 2 (M14).

    Methods: In this phase III, multi-center study (NCT02581410), open-label, 2 parallel groups of group-matched adults ≥65 years of age, HZ-PreVac and HZ-NonVac, received 2 RZV doses 2 months apart. Humoral and cellular immune responses were evaluated at various time points up to M14. Solicited and unsolicited adverse events (AEs) were recorded for 7 and 30 days post each dose, respectively. Serious AEs (SAEs), HZ cases and potential immune-mediated diseases (pIMDs) were recorded throughout the study.

    Results: 215 participants were vaccinated in each group. No apparent differences, in pre-vaccination and persistence values of the anti-gE antibody GMCs (Figure 1) and CD4[2+] T-cell frequencies (Figure 2) were observed between HZ-PreVac and HZ-NonVac, up to M14. No clinically relevant differences in frequencies of solicited AEs, unsolicited AEs or SAEs between the 2 groups were observed. Six pIMDs (2 in HZ-PreVac group and 4 in HZ-NonVac group), were reported up to M14 (Table 1).

    Conclusion: In both groups, RZV-induced humoral and cellular immune responses persisted above baseline up to M14 at similar levels, irrespective of previous ZVL administration. Safety profile was similar regardless of previous ZVL vaccination.

    Funding: GlaxoSmithKline Biologicals SA

     

     

    Tomas Mrkvan, PhD, MSc1, Laura Campora, MD2, Grégory Catteau, MSc1, Martine Douha, MSc2, Katrijn Grupping, PhD2, Caroline Herve, PhD1, George Kalema, PhD3, Thomas Heineman, MD, PhD4, Nicola P. Klein, MD, PhD5, Himal Lal, MD6, Lidia Oostvogels, MD7 and Anne Schuind, MD8, (1)GSK Vaccines, Wavre, Belgium, (2)GSK, Wavre, Belgium, (3)Keyrus Biopharma, Lasne, Belgium, (4)GSK, King of Prussia, PA, USA; Current affiliation: Halozyme Therapeutics, San Diego, CA, (5)Kaiser Permanente Vaccine Study Center, Oakland, CA, (6)Pfizer Inc., King of Prussia, PA, (7)CureVac AG, Tübingen, Germany, (8)GSK, Rockville, MD

    Disclosures:

    T. Mrkvan, GSK: Employee and Shareholder , Salary and shares and share options .

    L. Campora, GSK: Employee and Shareholder , Salary .

    G. Catteau, GSK: Board Member , Salary .

    M. Douha, GSK: Employee , Salary .

    K. Grupping, GSK: Employee , Salary .

    C. Herve, GSK: Employee , Salary .

    G. Kalema, GSK: Consultant , Consulting fee .

    T. Heineman, GSK: Consultant , Employee and Shareholder , Consulting fee and Salary .

    N. P. Klein, GSK: Investigator , Research support . Sanofi Pasteur: Investigator , Research support . Merck: Investigator , Research support . Pfizer: Investigator , Research support . Protein Science: Investigator , Research support . MedImmune: Investigator , Research support . Dynavax: Investigator , Research support .

    H. Lal, GSK: Shareholder , Salary . Pfizer: Shareholder , Salary .

    L. Oostvogels, GSK: Employee , Salary and stock and stock options .

    A. Schuind, GSK: Employee and Shareholder , Salary .

    See more of: Clinical Trials
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.